Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTSLI08)

DTT Name	Adenosine receptor (ADOR)
Synonyms	P1 receptor
Gene Name	NO-GeName
DTT Type	Successful target	[1]
Related Disease	Chronic obstructive pulmonary disease [ICD-11: CA22]
BioChemical Class	GPCR rhodopsin
UniProt ID	NOUNIPROTAC
TTD ID	T25663

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This DTT

1 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Theophylline	DMRJFN9	Chronic obstructive pulmonary disease	CA22	Approved	[1], [2]
------------------------------------------------------------------------------------

2 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DIADENOSINE TETRAPHOSPHATE	DMTJOEL	Cardiac arrhythmias	BC9Z	Phase 2	[3], [4]
NIR178	DMPER4A	Non-hodgkin lymphoma	2B33.5	Phase 2	[5]
------------------------------------------------------------------------------------

1 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
M-216765	DMUIGM3	Hypertension	BA00-BA04	Terminated	[6]
------------------------------------------------------------------------------------

3 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
8-sulfophenyl theophylline	DMOHB3Z	Discovery agent	N.A.	Investigative	[7]
GNF-PF-2224	DM26UKN	Discovery agent	N.A.	Investigative	[7], [8], [9], [10]
SPT	DM94RJW	Discovery agent	N.A.	Investigative	[11]
------------------------------------------------------------------------------------

References

1	Emerging adenosine receptor agonists. Expert Opin Emerg Drugs. 2007 Sep;12(3):479-92.
2	Role of adenosine in airway inflammation in an allergic mouse model of asthma. Int Immunopharmacol. 2006 Jan;6(1):36-45.
3	Negative chronotropic and inotropic effects exerted by diadenosine hexaphosphate (AP6A) via A1-adenosine receptors. Br J Pharmacol. 1996 Nov;119(5):835-44.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	US patent application no. 2010,0009,934, Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders.
7	Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J Invest Dermatol. 2001 Dec;117(6):1594-600.
8	Influence of the antagonist of adenosine A1 receptors, 8-cyclopentyl-1 ,3-dipropylxanthine, upon the anticonvulsant activity of antiepileptic drugs in mice. Przegl Lek. 2008;65(11):759-63.
9	Potent adenosine receptor antagonists that are selective for the A1 receptor subtype. Mol Pharmacol. 1987 Mar;31(3):247-52.
10	Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol Sci. 1996 Mar;17(3):108-13.
11	Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol. 1995 Mar;27(3):883-92.